Advanced BioDesign receives €14.3 M from Xerys Invest to continue its ODYSSEY trial
This agreement with its historic shareholder comes two months after the start of the first-in-human “ODYSSEY” clinical trial targeting acute myeloid leukemia. This capital injection of €14.3 million by Advanced … Read more